Dimerix Ltd
ASX:DXB

Watchlist Manager
Dimerix Ltd Logo
Dimerix Ltd
ASX:DXB
Watchlist
Price: 0.54 AUD -2.7%
Market Cap: 324.2m AUD

Operating Margin
Dimerix Ltd

-524.3%
Current
-76 055.5%
Average
-4.3%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-524.3%
=
Operating Profit
-31m
/
Revenue
5.9m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
AU
Dimerix Ltd
ASX:DXB
323.2m AUD
-524%
IL
Can Fite Biopharma Ltd
TASE:CANF
707T ILS
-1 487%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
391.9B USD
33%
US
Amgen Inc
NASDAQ:AMGN
173.8B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
149.7B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.8B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.8B USD
28%
AU
CSL Ltd
ASX:CSL
81.8B AUD
26%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
51.2B USD
8%
No Stocks Found

Dimerix Ltd
Glance View

Market Cap
323.2m AUD
Industry
Biotechnology

Dimerix Ltd. engages in the investment in research and development of biopharmaceutical drugs. The company is headquartered in Melbourne, Victoria. The firm is engaged in the development of new therapies in areas with unmet medical need. The firm is developing four product indications: Focal Segmental Glomerulosclerosis (FSGS), respiratory complications associated with COVID-19, diabetic kidney disease, and DMX-700 for Chronic Obstructive Pulmonary Disease (COPD), as well as the its Receptor-HIT assay technology. The Company’s pipeline products include DMX-200, DMX-700 and DMX-XXX. DMX-200, which is developed for FSGS, COVID-19 pneumonia patient in ICU and respiratory complications in COVID-19 patients is under Phase III clinical trial. DMX-200, which is developed for diabetic kidney disease is under Phase II clinical trial. DMX-700, which is developed for COPD is under Phase I clinical trial. DMX-XXX is under Phase I clinical trial.

DXB Intrinsic Value
0.13 AUD
Overvaluation 75%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-524.3%
=
Operating Profit
-31m
/
Revenue
5.9m
What is the Operating Margin of Dimerix Ltd?

Based on Dimerix Ltd's most recent financial statements, the company has Operating Margin of -524.3%.

Back to Top